TORNTPHARMNSETorrent Pharmaceuticals Limited· PharmaceuticalsLowNeutral
Announced Tue, 29 Jul · 16:18 IST

Torrent Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2025

Board & Shareholder Meetings View source PDF

TORNTPHARM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Torrent Pharmaceuticals held its 52nd AGM on July 28, 2025, where shareholders approved the standalone and consolidated financial statements for FY25. The meeting confirmed an interim dividend of ₹26 per share and declared a final dividend of ₹6 per share (face value ₹5), taking total FY25 dividends to ₹32 per share. Aman Mehta, who retires by rotation, was re-appointed as Director and also appointed as Managing Director with approved remuneration. Shareholders also approved a sharp increase in the company's borrowing limit from ₹15,000 crore to ₹26,000 crore, along with enabling resolutions for issuing equity shares, convertible bonds or debentures, and creating charges on company assets.

Likely market impact

The ₹11,000 crore jump in the borrowing ceiling signals a major funding push, likely for acquisitions, capex, or debt refinancing, which could increase leverage but also fuel growth. The total dividend of ₹32 per share offers steady income to shareholders, while the approval to issue new equity or convertibles hints at potential dilution down the line. Appointment of Aman Mehta as Managing Director brings leadership continuity.